XNCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

29.83M

-43.5%

-0.587

-5.32%

25.59M

-21.82%

-0.647

-1.95%

26.00M

-40.39%

-0.666

+62.37%

Estimates Revision

The market is revising Downward the revenue expectations for Xencor, Inc. (XNCR) for FY2025, with the revenue forecasts being adjusted by -6.04% over the past three months. During the same period, the stock price has changed by 96.35%.

Revenue Estimates for FY2025

Revise Downward

-6.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-27.52%

In Past 3 Month

Stock Price

Go Up

+96.35%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is 24.00 USD with a low forecast of 6.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

1 Sell

Moderate Buy

Current: 16.670

Low

6.00

Averages

24.00

High

42.00

Current: 16.670

Low

6.00

Averages

24.00

High

42.00

Truist

NULL -> Buy

initiated

$29

2025-11-24

Reason

Truist

Price Target

$29

2025-11-24

initiated

NULL -> Buy

Reason

Truist initiated coverage of Xencor with a Buy rating and $29 price target. Lead program, TL1A, has early data suggesting potential for sustained target engagement and the company's broader immunology and inflammation pipeline leverages Xencor's expertise in T-cell engagers, supported by its "deep oncology roots" and prior validation through xaluritamig, the analyst tells investors.

JPMorgan

Overweight -> Overweight

downgrade

$20 -> $18

2025-11-06

Reason

JPMorgan

Price Target

$20 -> $18

2025-11-06

downgrade

Overweight -> Overweight

Reason

JPMorgan lowered the firm's price target on Xencor to $18 from $20 and keeps an Overweight rating on the shares following the Q3 report.

Cantor Fitzgerald

NULL -> Overweight

maintain

$40 -> $42

2025-11-06

Reason

Cantor Fitzgerald

Price Target

$40 -> $42

2025-11-06

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Xencor to $42 from $40 and keeps an Overweight rating on the shares. By this time next year, Cantor expects Xencor could have a recommended Phase 3 dose identified for two different T-cell engage antibodies, with Phase 3s both starting in 2027, as well as a Phase 2b UC study of long-acting TL1A antibody '942 largely or even fully enrolled, the analyst tells investors in a research note.

Barclays

Etzer Darout

Underweight -> Overweight

upgrade

$6 -> $23

2025-10-29

Reason

Barclays

Etzer Darout

Price Target

$6 -> $23

2025-10-29

upgrade

Underweight -> Overweight

Reason

Barclays analyst Etzer Darout double upgraded Xencor to Overweight from Underweight with a price target of $23, up from $6. The firm has a more positive outlook on the company's pipeline following updates at the AACR-NCI-EORTC Conference. XNCR's recent updates for XmAb819, a first-in-class ENPP3 x CD3 bispecific T-cell engager in development for advanced clear cell renal cell carcinoma, and XmAb541 in CLDN6+ tumors were positive and exceeded expectations, the analyst tells investors in a research note. Barclays now values these programs at $6 per share.

RBC Capital

Gregory Renza

Outperform

maintain

$15 -> $18

2025-10-27

Reason

RBC Capital

Gregory Renza

Price Target

$15 -> $18

2025-10-27

maintain

Outperform

Reason

RBC Capital analyst Gregory Renza raised the firm's price target on Xencor to $18 from $15 and keeps an Outperform rating on the shares. The firm cites the company's phase 1 data on XmAb819 anti-ENPP3/anti-CD3 bispecific antibody in ccRCC at the AACR-NCI-EORTC conference, noting that its 25% Objective Response Rate in heavily pretreated patients is indicative of a drug that can compete on efficacy, while the manageable CRS - Cytokine Release Syndrome - with a generally well-tolerated profile should enable broad use and potential for outpatient administration, the analyst tells investors in a research note.

BofA

Neutral

maintain

$14 -> $15

2025-10-27

Reason

BofA

Price Target

$14 -> $15

2025-10-27

maintain

Neutral

Reason

BofA raised the firm's price target on Xencor to $15 from $14 and keeps a Neutral rating on the shares after the company shared results from XmAb819 in a Phase 1 dose escalation study in ccRCC at the Triple Meeting. The firm, which sees promise in the pipeline but sees early dose escalation readouts as unlikely to be conclusive, updated its model to increase peak penetration for XmAb819 to 15% from 13% and probability of success from 18% to 22%, the analyst noted.

Valuation Metrics

The current forward P/E ratio for Xencor Inc (XNCR.O) is -6.38, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Xencor Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.10

Current PE

-6.38

Overvalued PE

32.41

Undervalued PE

-36.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

11.72

Current EV/EBITDA

-4.27

Overvalued EV/EBITDA

81.03

Undervalued EV/EBITDA

-57.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.53

Current PS

10.72

Overvalued PS

20.62

Undervalued PS

8.45

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 160.17% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 160.17% over the last month.

Sold

Bought

XNCR News & Events

Events Timeline

No data

News

3.5

12-09Newsfilter

Xencor Extends Ultomiris Patent to 2028, Anticipates $100M to $120M in Additional Revenue

4.0

11-06Benzinga

JP Morgan Keeps Overweight Rating on Xencor, Reduces Price Target to $18

4.0

11-06Benzinga

RBC Capital Reaffirms Outperform Rating for Xencor and Increases Price Target to $19

People Also Watch

Frequently Asked Questions

What is Xencor Inc (XNCR) stock price today?

The current price of XNCR is 16.67 USD — it has increased 0.91 % in the last trading day.

What is Xencor Inc (XNCR)'s business?

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

What is the price predicton of XNCR Stock?

What is Xencor Inc (XNCR)'s revenue for the last quarter?

Xencor Inc revenue for the last quarter amounts to 21.00M USD, increased 18.00 % YoY.

What is Xencor Inc (XNCR)'s earnings per share (EPS) for the last quarter?

Xencor Inc. EPS for the last quarter amounts to -0.08 USD, decreased -88.89 % YoY.

What changes have occurred in the market's expectations for Xencor Inc (XNCR)'s fundamentals?

How many employees does Xencor Inc (XNCR). have?

Xencor Inc (XNCR) has 250 emplpoyees as of December 15 2025.

What is Xencor Inc (XNCR) market cap?

Today XNCR has the market capitalization of 1.18B USD.